Skip to main content
CLLS logo

Cellectis S.A.

CLLSNASDAQHealthcareBiotechnology

$1.11Today:- (-)1Y −75.55%

As of Oct 15, 2026 close

Market cap
$111.22M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.09$5.48
Volume (live)
-
Avg. volume (3M)
164.78K

Cellectis (CLLS) Income Statement

Cellectis reported revenue of $72.95M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 75.8% from $41.51M a year earlier. Cellectis posted a net loss of $67.59M, compared with a net loss of $36.76M a year earlier. Gross margin was 86.6% and operating margin -45.3%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $5.23M, down 68.7% from the same quarter a year earlier.

Cellectis Income Statement Analysis

Values in millions USD

Scroll to see more
Cellectis S.A. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue72.9541.510.7619.1730.3559.5615.1912.7325.19
Cost of Revenue9.809.187.428.481.841.9511.392.742.62
Gross Profit63.1532.32-6.6610.6928.5057.613.809.9922.57
Operating Expenses
Research & Development93.5290.5487.6597.50117.8477.0592.0476.5779.23
Selling, General & Administrative8.608.428.128.9022.8822.5143.0247.2544.75
Operating Expenses96.2391.8890.64100.35131.9899.92127.35115.08115.22
Operating Income-33.08-59.55-97.30-89.67-103.48-42.31-123.55-105.09-92.65
Other Income/Expense
Interest Income9.5011.283.611.120.721.396.986.791.97
Interest Expense8.117.455.313.794.17-2.412.960.720.56
Other Income/Expense-34.9418.97-16.356.069.740.348.3416.76-11.03
Income
Income Before Tax-68.02-36.76-116.47-98.60-96.75-53.58-115.21-88.33-103.68
Income Tax Expense-0.420.000.370.090.000.000.000.00-13.20
Net Income-67.59-36.76-101.06-106.14-114.20-81.07-102.09-78.69-99.37
Net Income - Continuous Operations-67.59-36.76-116.84-98.69-96.75-81.07-102.09-78.69-99.37
Net Income - Discontinued Operations--8.39-15.35-28.36----
EBITDA-39.85-9.46-92.64-76.38-78.43-34.68-105.73-93.79-108.08
EBIT-59.91-29.31-111.16-94.81-92.58-42.31---
Depreciation & Amortization20.061.482.011.895.737.636.882.383.37
Earnings Per Share
Basic EPS-1.00--2.00-2.00-2.00-2.00-2.00-2.00-3.00
Diluted EPS-1.00--2.00-2.00-2.00-2.00-2.00-2.00-3.00
Basic Shares Outstanding100.2890.5757.0145.5542.4542.5042.4440.7735.69
Diluted Shares Outstanding100.2890.5757.0145.5542.4542.5042.4440.7735.69

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Cellectis Financial Statements

What was Cellectis's revenue in fiscal 2025?

Cellectis reported revenue of $72.95M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 75.8% from $41.51M a year earlier.

Is Cellectis profitable?

No. Cellectis reported a net loss of $67.59M in fiscal 2025. In fiscal 2024 it lost $36.76M.

What is Cellectis's operating margin?

Cellectis's operating income was −$33.08M on revenue of $72.95M in fiscal 2025, an operating margin of -45.3%, compared with -143.5% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition